RxDoctor Payments Data

Lindsay Ferraro, MD

Neurology · Saratoga Springs, NYNPI 1194003889

Payments from drug & device makers

$10,646in general payments, 2019–2025

Across 35 payments — averaging $304.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$10K
  • SK Life Science, Inc.$352
  • Argenx US, Inc.$115
  • Livanova USA, Inc.$91
  • Amneal Pharmaceuticals LLC$79
  • Teva Pharmaceuticals USA, Inc.$58
  • plus $101 from 4 others

What the payments were for

  • Speaking & faculty fees$8,49180%
  • Travel & lodging$8918%
  • Food & beverage$1,26512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,646 in reported general payments places this provider in the 70th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$47,269
Medicare patients
315
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4645$695,277
XcopriCenobamate167$233,227
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$170,797
Gamunex-CImmune Globul G/Gly/Iga Avg 4636$169,681
NuplazidPimavanserin Tartrate32$160,463
AptiomEslicarbazepine Acetate50$117,645
IngrezzaValbenazine Tosylate14$113,185
UbrelvyUbrogepant70$100,871
Nurtec OdtRimegepant Sulfate63$95,568
Ajovy AutoinjectorFremanezumab-Vfrm82$84,075
EpidiolexCannabidiol (Cbd)14$50,912
ValtocoDiazepam19$45,689
Emgality PenGalcanezumab-Gnlm50$43,429
Lacosamide201$38,242
BriviactBrivaracetam32$37,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$11$271,45690 claims
SK Life Science, Inc.Xcopri$352$233,227167 claims
AbbVieUbrelvy, Qulipta$56$121,25384 claims
Neurocrine Biosciences, Inc.Ingrezza$20$113,18514 claims
Neurelis, Inc.Valtoco$9,851$45,68919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,623 neurology providers in New York.

Other neurology in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →